跳至主要内容
临床试验/NCT01114074
NCT01114074Unknown不适用

The Influence of the Proteins of the Contact Activation System on Thrombus Formation Under Different Flow-conditions in Blood

Maastricht University Medical Center1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
46
试验地点
1
主要终点
Thrombus formation, stability and break down

研究概览

简要总结

Rationale: Cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. Clinical studies indicate an important role for the proteins of the contact activation system (coagulation factor XII (FXII), FXI, prekallikrein and high molecular weight kininogen (HMWK)) on the risk of cardiovascular disease. There is substantial evidence from mouse studies that FXII and FXI participate in the formation and stability of thrombi and in vitro studies showed that collagen is able to activate FXII and hereby stimulate thrombin formation and potentiate the formation of platelet-fibrin thrombi. The investigators want to determine the role of the proteins of the contact activation system in platelet mediated thrombus formation in human blood.

Objective: The investigators will study the effects of the proteins of the contact activation system on platelet mediated thrombus formation, embolization and degradation on collagen in a perfusion flow model.

Study design: Blood will be collected from human volunteers via a venipuncture in the forearm. Each volunteer will donate maximally four times 30 ml of blood over a period of two days. This blood is used in perfusion flow experiments: blood flows over a coverslip covered with collagen in a flow chamber. The investigators will vary several conditions such as the concentration of the proteins and the shear rate. For perfusion flow experiments, the investigators need fresh whole blood because platelets are viable for four hours. After this time, new blood is needed.

Study population: For this study the investigators need blood from human volunteers with a coagulation defect in one of the proteins of the contact activation system, e.g. FXII, FXI, prekallikrein or HMWK and controls without any coagulation defects.

Main study parameters/endpoints: The investigators main study endpoint is the ex vivo formation of platelet-mediated thrombi on collagen in a perfusion flow model. The investigators hypothesize that thrombi formed from blood of patients deficient in FXII or FXI are less stable than those formed from blood from controls.

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient group:
  • Age: ≥ 18 years
  • Deficiency in factor XII, factor XI, prekallikrein or high molecular weight kininogen
  • Control group:
  • Age: ≥ 18 years

排除标准

  • (Other) Coagulation defects
  • Symptoms of active disease
  • The use of antiplatelet drugs
  • The use of aspirin/ascal

结局指标

主要结局

Thrombus formation, stability and break down

时间窗: Up to 36 months

Using perfusion-flow experiments the formation, stability and break down of clots formed from the blood of the study participants will be determined.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验